DermaSensor has raised $5m, with the close of its Series B extension financing round following its establishment of four new partnerships earlier this month.
The latest financing tranche for the Miami-based developer of an AI-based skin cancer diagnostic, which featured participation from a mix of institutional and strategic investors, alongside the launch of a community investment round on Wefunder, follows the initial $16m Series B financing round’s close in October 2025. The extended financing brings DermaSensor’s total funds raised to date to around $48m.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Authorised for use by primary care physicians and non-specialist clinicians to evaluate suspicious skin lesions including melanoma, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC) in adult patients, DermaSensor’s namesake device secured de novo clearance from the US Food and Drug Administration (FDA) in January 2024. DermaSensor is also CE-marked in Europe, having achieved the designate as a Class IIb medical device in June 2026.
Shortly preceding the extended financing round’s close, DermSensor established four new partnerships. Announced on 1 September, these include an approved supplier relationship with Henry Schein, a new customer partnership with a major US healthcare institution, and a partnership with Medical Place as DermaSensor’s exclusive reseller to the US Department of Veterans Affairs (VA).
Together, these partnerships establish a commercial infrastructure to scale access to DermaSensor across the US and accelerate its growth, the company stated.
DermaSensor’s CEO, Cody Simmons, commented: “Our professional investor partners have supported us through every phase of building this new medical device category. Opening the financing on Wefunder is about extending that ownership to the physicians and patients who are living the problem we’re solving, given that one in five Americans are affected by skin cancer.”
Originally developed at Boston University, DermaSensor uses a combination of elastic scattering spectroscopy (ESS) and AI to provide risk assessment results for suspicious skin lesions. In published studies, the device has demonstrated 96% device sensitivity across the three most common skin cancers of melanoma, BCC, and SCC, while reducing missed skin cancer referrals by more than 50%.
An estimated 234,680 new cases of melanoma will be diagnosed in the US in 2026, which includes around 112,000 invasive cases and 122,680 non-invasive cases, as per the Skin Cancer Foundation.
